Associated Papers
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.
Yee SW et al.
Biorxiv : the Preprint Server for Biology, 2023
37333090 (PubMed )
Supplement: media-2.xlsx › S2_gnomAD_v2.1
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A.
Rafehi M et al.
Frontiers in Pharmacology, 2019
Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP et al.
Medicine, 2018
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.
Seitz T et al.
Genome Medicine, 2015
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H et al.
The Aaps Journal, 2013
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.
Lozano E et al.
Biomed Research International, 2013
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
Chen L et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Select a paper to view details